On September 3, WUXI BIO rose 3.27% in regular trading, trading at HK$50.65/share with turnover of HK$309 million, rebounding from a recent streak of profit-taking.

On the news front, the company disclosed that it had cumulatively repurchased approximately 39.82 million shares between May 27 and July 7, involving a total consideration of approximately HK$1.272 billion, representing about 0.96% of total issued shares prior to the buyback. The average repurchase price was approximately HK$31.93 per share, significantly below the current trading price, underscoring management confidence in the company's intrinsic value. Meanwhile, peer CXO names also advanced, with Pharmaron up 4.91% and WuXi XDC up 3.45%, reflecting a broader recovery in sector sentiment. Institutional research has pointed to clear upward signals in CXO industry prosperity, citing easing external pressures, a global biotech funding recovery, and rising domestic business development activity as drivers of a new upcycle characterized by improving orders and sequential earnings momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)